Klin Padiatr 2013; 225(S 01): S45-S49
DOI: 10.1055/s-0033-1337963
Zum 80. Geburtstag von Prof. Riehm
© Georg Thieme Verlag KG Stuttgart · New York

Forschung in der Pädiatrischen Hämatologie [Deutschland, 1970–2000]

Research in Pediatric Hematology [Germany, 1970–2000]
K. Welte
1   Abteilung für Molekulare Hämatopoese, Kinderklinik, Medizinische Hochschule Hannover, Hannover
› Author Affiliations
Further Information

Publication History

Publication Date:
22 May 2013 (online)

Zusammenfassung

Professor Riehm war nicht nur ein exzellenter pädiatrischer Onkologe, sondern auch ein hervorragender Hämatologe. Er war Mentor auch für junge Wissenschaftler, die hämatologische Forschung als ihren Schwerpunkt betrachteten. In den 1970er Jahren hat er die Gerinnungsforschung in seiner Abteilung gefördert, in den 1980iger Jahren die Erforschung hämatopoe­tischer Wachstumsfaktoren. Er war in den 1990iger Jahren einer der Ersten in Europa, die hämatopoetische Wachstumsfaktoren als supportive Therapie im ALL-BFM Protokoll eingesetzt haben und hat auch mitgeholfen, das internationale Register für schwere chronische Neutropenien in seiner Abteilung zu etablieren. Dieses Gespür für die aktuellen Forschungsrichtungen der Zeit zeichnet ihn nicht nur als Pionier der Leukämietherapiestudien aus, sondern auch als Pionier in der Hämatologie. Er schuf die Umgebung, in der Forschung blühen konnte.

Abstract

Professor Riehm was not only an excellent pediatric oncologist, but also an excellent hematologist. He was a mentor also for young scientists who were interested in hematological research as his/her main focus. In the 1970s he has promoted research in coagulation disorders, during 1980s he supported the investigation on hematopoetic growth factors. During the 1990s he was one of the first in Europe who have used hematopoietic growth factors as a supportive therapy in the protocol ALL-BFM and has also helped to set up the International Registry for Severe Chronic Neutropenias [SCNIR] in his Department. The sense of the top research directions of the time distinguishes him not only as a pioneer of the leukaemia therapy studies, but also as a pioneer in hematology. He created the enviroment in which research could blossom.

 
  • Literatur

  • 1 Ballmaier M, Germeshausen M, Schulze H et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97: 139-146
  • 2 Bonilla M, Gillio AP, Ruggierio M et al. Effects of recombinant human granulocyte colony stimulating factor on neutropenia of patients with congenital agranulocytosis. N Engl J Med 1989; 320: 1574-1580
  • 3 Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Australian Journal of Experimental Biology and Medical Science 1966; 44: 287-300
  • 4 Broudy VC, Kaushansky K. Thrombopoietin, the c-mpl ligand, is a major regulator of platelet production. J Leukoc Biol 1995; 57: 719-725
  • 5 Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony-stimulating factor from mouse lung conditioned medium. J Biol Chem 1977; 252: 1998-2003
  • 6 Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-170
  • 7 Dührsen U, Villeval JL, Boyd J et al. Effects of recombinant human granulocyte colony-stimulating factor on he- matopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-2081
  • 8 Gadner H, Welte K, Siegert M et al. Die Fibrin-Fibrinogen Spaltprodukte während der Induktionsbehandlung der akuten Leukämie des Kindes. Monatsschr Kinderheilk 1979; 27: 260-261
  • 9 Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-1422
  • 10 Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood 2007; 109: 93-99
  • 11 Ichikawa Y, Pluznik DH, Sachs L. In vitro control of the development of macrophage and granulocyte colonies. Proc Natl Acad Sci USA 1966; 56: 488-495
  • 12 Jiang X, Lopez A, Holyoake T et al. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 1999; 96: 12804-12809
  • 13 Klein C, Grudzien M, Appaswamy G et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia [Kostmann disease]. Nat Genet 2007; 39: 86-92
  • 14 Körbling M, Freireich EJ. Twenty-five years of peripheral blood stem cell transplantation. Blood 2011; 117: 6411-6416
  • 15 McDonald JD, Lin FK, Goldwasser E. Cloning, Sequencing, and Evolutionary Analysis of the Mouse Erythropoietin Gene. Mol Cell Biol 1986; 6: 842-848
  • 16 Metcalf D. The CSFs and Cancer. Nat Rev Cancer 2010; 10: 425-434
  • 17 Moore MAS, Williams N, Metcalf D et al. In vitro colony formation by normal and leukemic human hematopoietic cells: Interaction between colony-forming and colony-stimulating cells. J Natl Cancer Inst 1973; 50: 591-602
  • 18 Pabst T, Vellenga E, van Putten W et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012; 119: 5367-5373
  • 19 Riehm H, Gadner H, Welte K. Die West-Berliner Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes – Erfahrungsbericht nach 6 Jahren. Klin Pädiatr 1977; 189: 89-102
  • 20 Ringden O, Labopin M, Bacigalupo A et al. Transplantation of peripheral blood stem cells compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655-4664
  • 21 Rosenberg PS, Zeidler C, Bolyard AA et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010; 150: 196-199
  • 22 Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs fil- grastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Trans-plantation. Bone Marrow Transplant 1998; 21: 995-1003
  • 23 Skokowa J, Lan D, Thakur BK et al. Nampt is esential for the G-CSF induced myeloid differentiation via a NAD+-sirtuin-dependent pathway. Nat Med 2009; 15: 151-158
  • 24 Souza L, Boone TC, Lai PH et al. Recombinant pluripotent human granulocyte colony-stimulating factor induces proliferation and differentiation of normal and leukemic myeloid cells. Science 1986; 232: 61-65
  • 25 Stanley ER, Heard PM. Factors regulating macrophage production and growth: Purification and some properties of the colony stimulating factor from medium conditioned by mouse L cells. J Biol Chem 1977; 252: 4305-4312
  • 26 Venuta S, Mertelsmann R, Welte K et al. Acute lymphoblastic leukemias produce Interleukin 2 [T cell growth factor] and have an altered mechanism of Interleukin 2 production as detected by a T cell monoclonal antibody. Blood 1983; 61: 781-789
  • 27 Welte K, Wang CY, Mertelsmann R et al. Purification of human Interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 1982; 156: 454-464
  • 28 Welte K, Platzer E, Lu L et al. Purification and biochemical characterization of human pluripotent hematopoietic colony stimulating factor. Proc Natl Acad Sci USA 1985; 82: 1526-1530
  • 29 Welte K, Bonilla MA, Gillio AP et al. Recombinant human G-CSF: Effects on hematopoiesis in normal and cyclophosphamide treated primates. J Exp Med 1987; 165: 941-948
  • 30 Welte K, Zeidler C, Reiter A et al. Differential effects of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor in children with severe congenital neutropenia. Blood 1990; 75: 1056-1063
  • 31 Welte K, Reiter A, Mempel K et al. A randomised phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996; 87: 3143-3150
  • 32 Welte K, Riehm H. Granulocyte Colony-Stimulating Factor in Children with Acute Lymphoblastic Leukemia. N Engl J Med 1997; 337: 1320
  • 33 Welte K, Zeidler C, Dale D. Severe congenital neutropenia. Semin Hematol 2006; 43: 189-195
  • 34 Welte K, Gabrilove J, Bronchud MH et al. Filgrastim [r-metHuG-CSF]: the first ten years. Blood 1996; 88: 1907-1929
  • 35 Wong GG, Witek JS, Temple PA et al. Human GM-CSF: Molecular cloning of the complementary DNA and purificationof the natural and recombinant proteins. Science 1985; 228: 810-815
  • 36 Young DC, Wagner K, Griffin JD. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J Clin Invest 1987; 79: 100-106
  • 37 Zeidler C, Germeshausen M, Klein C et al. Clinical implications of ELA2-, HAX1-, and G-CSF-receptor [CSF3R] mutations in severe congenital neutropenia. Br J Haematol 2009; 144: 459-467